169 related articles for article (PubMed ID: 24996975)
1. Orphan drug designation for pracinostat, volasertib and alvocidib in AML.
Bose P; Grant S
Leuk Res; 2014 Aug; 38(8):862-5. PubMed ID: 24996975
[No Abstract] [Full Text] [Related]
2. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
Zeidner JF; Karp JE
Leuk Res; 2015 Dec; 39(12):1312-8. PubMed ID: 26521988
[TBL] [Abstract][Full Text] [Related]
3. Emergence of crenolanib for FLT3-mutant AML.
Fathi AT
Blood; 2013 Nov; 122(22):3547-8. PubMed ID: 24263951
[TBL] [Abstract][Full Text] [Related]
4. Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.
Wiernik PH
Expert Opin Investig Drugs; 2016 Jun; 25(6):729-34. PubMed ID: 26998706
[TBL] [Abstract][Full Text] [Related]
5. Novel drugs for older patients with acute myeloid leukemia.
Montalban-Bravo G; Garcia-Manero G
Leukemia; 2015 Apr; 29(4):760-9. PubMed ID: 25142817
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
Schnerch D; Schüler J; Follo M; Felthaus J; Wider D; Klingner K; Greil C; Duyster J; Engelhardt M; Wäsch R
Oncotarget; 2017 Mar; 8(13):21153-21166. PubMed ID: 28416751
[TBL] [Abstract][Full Text] [Related]
7. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.
Garcia-Manero G; Abaza Y; Takahashi K; Medeiros BC; Arellano M; Khaled SK; Patnaik M; Odenike O; Sayar H; Tummala M; Patel P; Maness-Harris L; Stuart R; Traer E; Karamlou K; Yacoub A; Ghalie R; Giorgino R; Atallah E
Blood Adv; 2019 Feb; 3(4):508-518. PubMed ID: 30760466
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
Rudolph D; Impagnatiello MA; Blaukopf C; Sommer C; Gerlich DW; Roth M; Tontsch-Grunt U; Wernitznig A; Savarese F; Hofmann MH; Albrecht C; Geiselmann L; Reschke M; Garin-Chesa P; Zuber J; Moll J; Adolf GR; Kraut N
J Pharmacol Exp Ther; 2015 Mar; 352(3):579-89. PubMed ID: 25576074
[TBL] [Abstract][Full Text] [Related]
9. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
[TBL] [Abstract][Full Text] [Related]
10. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
Nishi R; Shigemi H; Negoro E; Okura M; Hosono N; Yamauchi T
BMC Cancer; 2020 Oct; 20(1):984. PubMed ID: 33046037
[TBL] [Abstract][Full Text] [Related]
12. Novel drug targets in acute leukemia.
Stock W
Clin Adv Hematol Oncol; 2015 Aug; 13(8):493-5. PubMed ID: 26351809
[No Abstract] [Full Text] [Related]
13. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.
Gjertsen BT; Schöffski P
Leukemia; 2015 Jan; 29(1):11-9. PubMed ID: 25027517
[TBL] [Abstract][Full Text] [Related]
14. Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?
Bose P; Grant S
Expert Rev Hematol; 2012 Oct; 5(5):475-8. PubMed ID: 23146050
[No Abstract] [Full Text] [Related]
15. [New therapeutic agents for acute myeloid leukemia].
Hosono N
Rinsho Ketsueki; 2019; 60(9):1108-1119. PubMed ID: 31597834
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A
Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
[TBL] [Abstract][Full Text] [Related]
17. Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.
Ottmann OG; Müller-Tidow C; Krämer A; Schlenk RF; Lübbert M; Bug G; Krug U; Bochtler T; Voss F; Taube T; Liu D; Garin-Chesa P; Döhner H
Br J Haematol; 2019 Mar; 184(6):1018-1021. PubMed ID: 29882583
[No Abstract] [Full Text] [Related]
19. Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition.
Moison C; Lavallée VP; Thiollier C; Lehnertz B; Boivin I; Mayotte N; Gareau Y; Fréchette M; Blouin-Chagnon V; Corneau S; Lavallée S; Lemieux S; Marinier A; Hébert J; Sauvageau G
Blood Adv; 2019 Feb; 3(4):552-563. PubMed ID: 30782614
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.
Nakanishi T; Karp JE; Tan M; Doyle LA; Peters T; Yang W; Wei D; Ross DD
Clin Cancer Res; 2003 Aug; 9(9):3320-8. PubMed ID: 12960118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
